Positive Health Online
Your Country
Research: KARIM and COLLEAGUES,
Listed in Issue 300
Abstract
KARIM and COLLEAGUES, 1. Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, United Kingdom; 2. College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, United Kingdom; 3. Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, United Kingdom C.Dufes@strath.ac.uk sought to determine whether a novel tumour-targeted vesicular formulation of tocotrienol would suppress the growth of A431 epidermoid carcinoma and B16-F10 melanoma in vitro and in vivo.
Background
The therapeutic potential of tocotrienol, a member of the vitamin E family of compounds with potent in vitro anti-cancer properties, is limited by its inability to specifically reach tumours following intravenous administration.
Methodology
The purpose of this study is to determine whether a novel tumour-targeted vesicular formulation of tocotrienol would suppress the growth of A431 epidermoid carcinoma and B16-F10 melanoma in vitro and in vivo.
Results
In this work, we demonstrated that novel transferrin-bearing multi-lamellar vesicles entrapping α-T3 resulted in a dramatically improved (by at least 52-fold) therapeutic efficacy in vitro on A431 cell line, compared to the free drug. In addition, the intravenous administration of tocotrienol entrapped in transferrin-bearing vesicles resulted in tumour suppression for 30% of A431 and 60% of B16-F10 tumours, without visible toxicity. Mouse survival was enhanced by >13days compared to controls administered with the drug solution only.
Conclusion
This tumour-targeted, tocotrienol-based nanomedicine therefore significantly improved the therapeutic response in cancer treatment.
References
Karim R1, Somani S1, Al Robaian M1, Mullin M2, Amor R1, McConnell G1, Dufès C3. Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol. J Control Release. ;246:79-87. doi: 10.1016/j.jconrel.2016.12.014. Epub Dec 18 2016 . Jan 28 2017.
Comment
The above research demonstrated the the tumour-targeted, tocotrienol-based nanomedicine therefore significantly improved the therapeutic response in cancer treatment